Please login to the form below

Corlaner

This page shows the latest Corlaner news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.

Latest news

Amgen starts shipping Corlaner in US

Firm also reports healthy financial growth in the first quarter. . Amgen has started shipping its Corlaner heart failure therapy to wholesalers in the US just a few days after getting FDA ... Corlaner (ivabradine) - the first new medicine for chronic
FDA clears Amgen's Corlaner for heart failure

The FDA approved Corlaner (ivabradine) after a priority review for reducing the risk of hospitalisation for worsening heart failure in patients with stable, symptomatic chronic heart failure (CHF). . ... Corlaner's approval is based on the results of
Amgen banking on three launches in 2015

year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma. ... Despite the upbeat comments, Amgen did reveal that Corlaner and T-VEC have both been delayed by requests for

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Heart failure therapy embarks on a new era

Corlaner costs around the same as Entresto at around $4, 500 per year. ... Entresto and Corlaner are expected to account for the bulk of that increase, with Entresto taking the lion's share.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Director: Competitive Salary Offered

Account Manager / Account Director: Competative

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Business Director: Competitive Salary Offered

Global Business Development Director – Health Education: excellent commission

Senior Account Manager: Competitive Salary Offered

Account Director, Medical Education: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Medical Writer: Salary TBC

Medical Writer: Salary TBC

Associate Director: £75, 000-90, 000

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Senior Account Director development role to Business Director, H...: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....